Select Therapeutics Inc., of Cambridge, Mass., said the University of Toronto Innovations Foundation was issued U.S. Patent No. 5,968,894, which claims the use of verotoxin for the treatment of brain cancer, ovarian cancer, breast cancer and skin cancer. Select is the exclusive licensee of the patent.

Shearwater Polymers Inc., of Huntsville, Ala., was issued U.S. Patent No. 5,932,462 titled “Multiarmed, monofunctional polymer for coupling to molecules and surfaces.”

THM Biomedical Inc., of Duluth, Minn., was issued U.S. Patent No. 5,981,825 titled “Device and Methods for In Vivo Culturing of Diverse Cells.” The patent relates to the transport and culturing of cells in a diverse tissue lesion using a porous polymer implant.

Univera Pharmaceuticals Inc., of Broomfield, Colo., was issued U.S. Patent No. 5,965,540 for its compound, UP540, which is used as a treatment for inflammatory diseases.

Xanthon Inc., of Research Triangle Park, N.C., said the U.S. PTO has allowed the patent titled “Polymer-Electrodes for Detecting Nucleic Acid Hybridization and Method of Use Thereof.” It covers a device, apparatus and method for the detection of nucleic acids and proteins using the novel electrochemical process.